Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.

Abstract: A leakage current detection interrupter with fire protection means comprising: (i) a movable assembly housing; (ii) two fixed contact holders each having a fixed contact point; (iii) ) two movable contact holders each having a fixed end and a movable end with a movable contact point; (iv) a movable assembly that moves between a first position and a second position; (v) a resetting component; (vi) a resetting component spring; (vii) an electromagnetic tripping component, which, when energized, which is responsive to a fault condition, causes the movable assembly to be in the second position from the first position; (viii) an leakage current protection circuit assembled on a printed circuit board for detecting the fault condition; and (ix) a set of three electrical wires: a first wire, a second wire, and a third wire to an appliance, wherein the first wire and the second wire are protected by a plurality of protective shields.

Abstract: A sectional floor mat system of floor mats and edging sections or pieces that are removably engaged with the floor mats. The floor mat system includes at least one mat and sufficient edging to border at least one of the side edges of the at least one mat. In many embodiments, there is sufficient edging to border all side edges of the at least one mat, when multiple mats, if present, and connected together. The edging pieces of the invention, and other variations thereof, when combined with mats, provide a floor covering system that is easy for the user to set-up, disassemble as needed, and inhibit tripping on the edges of mats.

Abstract: The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.

Abstract: The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.

Abstract: The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is also provided.

Abstract: A leakage current detection interrupter with fire protection means, comprising: (i) a leakage current protection circuit, (ii) an electrical cord with metallic fire shields, and (iii) a fire protection circuit, wherein, in operation, the leakage current protection circuit and the fire protection circuit detect a fault condition including a leakage current, a ground fault and a fire hazard, and disconnect the source of electricity from the at least one user accessible load when leakage current, ground fault or fire hazard is detected. The electrical cord with metallic fire shields, the fire protection circuit, and the indicator circuit can be combined with any ground fault circuit interrupter, arc fault circuit interrupter, immerse detection circuit interrupter, appliance leakage current interrupter and electronic leakage current interrupter.

Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.

Abstract: A permanent-magnet ground fault circuit interrupter plug with self-diagnosing function having an enclosure and a permanent-magnet mechanism encased in the enclosure.

Abstract: A permanent-magnet ground fault circuit interrupter plug with self-diagnosing function having an enclosure and a permanent-magnet mechanism encased in the enclosure.

Abstract: The invention provides a process for preparing a conjugate comprising a cell binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell binding agent, which then is conjugated to a drug, as well as purification and holding steps, and optionally a tangential flow filtration (TFF) step.

Abstract: The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.

Abstract: The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.

Abstract: The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.